Target intelligence / Profile preview

Hes family bHLH transcription factor 5 (HES5)

Target: HES5
Molecular classification: Transcription factor, Basic helix-loop-helix (bHLH) protein, Chromatin-binding protein

Overview

HES5, or Hes family bHLH transcription factor 5, is a basic helix-loop-helix transcriptional repressor that acts as a critical downstream mediator of the Notch receptor signaling pathway. It plays an essential role in maintaining neural stem and progenitor cell identity by repressing differentiation-associated genes, acts as a negative regulator of neurogenesis, and is widely expressed in the central nervous system and other tissues. It functions in tissue patterning, cell fate determination, and embryonic segmentation. Dysregulation of HES5 has been linked to various diseases, including developmental disorders, cancers, major depression, pulmonary arterial hypertension, and multiple sclerosis. While not a common direct drug target, it is involved in pathways frequently modulated in disease and therapy[1][2][3][4][5].

Other names: Transcription factor HES-5BHLHB38bHLHb38Class B basic helix-loop-helix protein 38Hairy and enhancer of split 5HES5

Mechanism of action

Drugs targeting the Notch signaling pathway may indirectly influence HES5 expression or function. Epigenetic modulation may affect HES5 transcriptional repression activity.

Biological functions

Transcriptional repressionMaintenance of neural stem and progenitor cell identityNegative regulation of neurogenesisRegulation of cell differentiation in multiple tissuesRegulation of segmentation clock during embryogenesisRepression of serotonin receptor gene in serotonergic neuronsPromotion of smooth muscle cell proliferation (in pulmonary vasculature)

Disease associations

CancerDevelopmental diseases (including intellectual developmental disorder and axial skeletal defects)Neurodevelopmental disordersPulmonary arterial hypertensionMultiple sclerosis (regulation of oligodendrocyte maturation)Major depression and suicide (via regulation of serotonin receptor gene)

Safety considerations

Not directly applicable; as a transcription factor, direct targeting poses challenges including broad effects on gene expression and cell fate, complicating therapeutic interventions.Off-target effects if attempting to modulate HES5 by pharmacological means may impact stem cell populations or developmental pathways.

Interacting drugs

No approved or well-documented drugs directly targeting HES5 as a primary mechanism.

1 more in the full profile.

Biomarkers

HES5 expression levels have been suggested as biomarkers for cancer progression (e.g., cervical carcinoma), neurodevelopmental disorders, and remyelination in multiple sclerosis.Aberrant HES5 expression may serve as a biomarker for ineffective neural differentiation or the maintenance of undifferentiated cell states.

Beyond the preview

Go deeper on Hes family bHLH transcription factor 5 (HES5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hes family bHLH transcription factor 5 (HES5).

Explore the full profile